Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
Mara M. Epstein,
Bernard Rosner,
Elizabeth C. Breen,
Julie L. Batista,
Edward L. Giovannucci,
Larry Magpantay,
Jon C. Aster,
Scott J. Rodig,
Kimberly A. Bertrand,
Francine Laden,
Otoniel Martínez-Maza,
Brenda M. Birmann
Affiliations
Mara M. Epstein
Department of Medicine and the Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA, USA
Bernard Rosner
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Elizabeth C. Breen
UCLA AIDS Institute, Los Angeles, CA, USA;Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Julie L. Batista
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Edward L. Giovannucci
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Larry Magpantay
UCLA AIDS Institute, Los Angeles, CA, USA;Department of Obstetrics & Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Jon C. Aster
Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Scott J. Rodig
Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Kimberly A. Bertrand
Slone Epidemiology Center at Boston University, Boston, MA, USA
Francine Laden
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Otoniel Martínez-Maza
UCLA AIDS Institute, Los Angeles, CA, USA;Department of Obstetrics & Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA;Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Brenda M. Birmann
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk. We identified 598 incident lymphoma cases and 601 matched controls in Nurses’ Health Study and Health Professionals Follow-up Study participants with archived pre-diagnosis plasma samples and measured 13 immune marker levels with multiplexed immunoassays. Using multivariable logistic regression we calculated Odds Ratios (OR) and 95% Confidence Intervals (CI) per standard deviation unit increase in biomarker concentration for risk of non-Hodgkin lymphoma and major histological subtype, stratifying additional models by years (
